Data Snacks AI
Data Source Integration Status
12 new trials added today
3 status updates processed
8 new publications indexed
2 high-impact papers identified
1 new approval announced
2 advisory committee meetings scheduled
Featured Data Snacks
Trial Milestone Tracker
AI5 major Phase 3 readouts expected in Oncology this quarter, with Merck's MK-7189 and BMS's relatlimab combination as key ones to watch.
Regulatory Radar
AIFDA PDUFA dates clustering in Q3 2025 for immunology assets, with 3 JAK inhibitors and 2 IL-23 inhibitors awaiting decisions.
All Data Snacks
Shifting MOA Trends
AIBispecific antibodies gaining momentum in oncology pipeline with 24% YoY growth in clinical trials, primarily in hematologic malignancies.
Competitive Spend Spotlight
AINovartis increased R&D spend by 15% in Q1 2025, with 60% allocated to oncology and immunology programs, signaling strategic shift.
JAK Inhibitor Landscape in Immunology
AI4 competitors have JAK inhibitors in Phase 3 trials for RA, with potential approvals expected in 2026-2027.
Alzheimer's Treatment Trends
AIAnti-amyloid antibodies continue to dominate the pipeline, with 5 assets in late-stage development.
NASH Pipeline Developments
AIFXR agonists facing challenges in Phase 3 trials, with 2 recent failures suggesting need for combination approaches.